FS Medical Supplies, LLC v. TannerGAP, Inc.

District Court, W.D. North Carolina·Decided September 6, 2022·No. 3:21-cv-00501·Unknown

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE WESTERN DISTRICT OF NORTH CAROLINA CHARLOTTE DIVISION CASE NO. 3:21-CV-501-RJC-DCK

FS MEDICAL SUPPLIES, LLC, ) ) Plaintiff, ) ) v. ) ORDER ) TANNERGAP, INC., TANNER PHARMA ) UK LIMITED, RAYMOND FAIRBANKS ) BOURNE, and STEPHEN JOHN SCALIA, ) ) Defendants. )

THIS MATTER IS BEFORE THE COURT on “Plaintiff’s Motion To File A Document Under Seal” (Document No. 38). This motion has been referred to the undersigned Magistrate Judge pursuant to 28 U.S.C. § 636(b), and immediate review is appropriate. Having carefully considered the motion and the record, the undersigned will grant the motion, and direct Plaintiff to file a publicly-available redacted version of the Amended Complaint. BACKGROUND Plaintiff FS Medical Supplies, LLC (“Plaintiff” or “FSMS”) initiated this action with the filing of a Complaint (Document No. 1) on September 23, 2021. The original Complaint asserted claims against TannerGAP, Inc. (“TannerGAP”) and Tanner Pharma UK Limited (“Tanner Pharma UK”). (Document No. 1). On December 6, 2021, Defendants TannerGAP and Tanner Pharma UK filed a “Motion To Dismiss” (Document No. 15). The Court denied the motion to dismiss without prejudice, and directed the parties to conduct jurisdictional discovery. See (Document Nos. 20 and 21). The deadline for jurisdictional discovery, and for Plaintiff to file an Amended Complaint, was extended multiple times. (Document Nos. 23, 27, 36). Plaintiff filed the now pending “…Motion To File A Document Under Seal” (Document No. 38), along with a sealed “Amended Complaint” (Document No. 40), on August 12, 2022. The Amended Complaint asserts claims against TannerGAP, Tanner Pharma UK, Raymond Fairbanks

Bourne (“Bourne”) and Stephen John Scalia (“Scalia”) (all together “Defendants”) for: (1) Breach of Contract – Distribution Agreement; (2) Breach of Contract – Non-Circumvention Agreement; (3) Breach of Contract – Implied Covenant of Good Faith and Fair Dealing; and (4) Unfair and Deceptive Trade Practices. (Document No. 40, pp. 29-35). “TannerGAP, Inc. And Tanner Pharma UK Limited’s Memorandum In Response To Plaintiff’s Motion To File A Document Under Seal” (Document No. 53) was filed on August 25, 2022. “Plaintiff’s Response…” (Document No. 55) was filed on August 26, 2022.1 Defendants Bourne and Scalia have not responded to the pending motion. The pending motion is now ripe for review.

STANDARD OF REVIEW A party who seeks to seal any pleading must comply with the Local Rules of this Court. Local Civil Rule(“LCvR”) 6.1 provides in relevant part as follows: LCvR. 6.1 SEALED FILINGS AND PUBLIC ACCESS.

(a) Scope of Rule. To further openness in civil case proceedings, there is a presumption under applicable common law and the First Amendment that materials filed in this Court will be filed unsealed. This Rule governs any party’s request to seal, or otherwise restrict public access to, any materials filed with the Court or used in connection with judicial decision- making. As used in this Rule, “materials” includes pleadings and documents of any nature and in any medium or format.

1 The Court construes this filing as Plaintiff’s reply brief. See Local Rule 7.1(e). (b) Filing under Seal. No materials may be filed under seal except by Court order, pursuant to a statute, or in accordance with a previously entered Rule 26(e) protective order.

(c) Motion to Seal or Otherwise Restrict Public Access. A party’s request to file materials under seal must be made by formal motion, separate from the motion or other pleading sought to be sealed, pursuant to LCvR 7.1. Such motion must be filed electronically under the designation “Motion to Seal.” The motion must set forth:

(1) A non-confidential description of the material sought to be sealed; (2) A statement indicating why sealing is necessary and why there are no alternatives to filing under seal; (3) Unless permanent sealing is sought, a statement indicating how long the party seeks to have the material maintained under seal and how the matter is to be handled upon unsealing; and (4) Supporting statutes, case law, or other authority.

Local Rule 6.1 (emphasis added). It appears that the requirements of Local Rule 6.1(c)(1) through (4) have been met. DISCUSSION Plaintiff filed its motion to seal the Amended Complaint, consistent with the requirements of the parties’ “Stipulated Protective Order” (Document No. 25), but Plaintiff actually opposes sealing, or even redacting, the Amended Complaint. (Document Nos. 38, 39, and 55). In support of the motion to seal, Plaintiff notes that pursuant to the Protective Order, “a party may not publicly file documents or information contained in documents that have been marked as ‘Confidential.’” (Document No. 39, p. 3). See also (Document No. 25, p. 10). Plaintiff acknowledges that the Amended Complaint relies on and quotes approximately 100 Confidential documents provided by Defendants. Id. In response to the motion to seal, TannerGAP and Tanner Pharma UK (together, the “Corporate Defendants”) “join Plaintiff’s Motion to File a Document Under Seal.” (Document No. 53, p. 1). Corporate Defendants note that the Amended Complaint “relies in part on sensitive and proprietary information produced during jurisdictional discovery” that appears “to be derived from documents produced for purposes of jurisdictional discovery and designated ‘Confidential.’” (Document No. 53, p. 1).

Corporate Defendants “request only that portions of 13 paragraphs be sealed by redaction” and have filed a version of the Amended Complaint (Document No. 54) with proposed redactions. Id.; see also (Document No. 54). Corporate Defendants contend the proposed redactions “contain confidential, sensitive, and proprietary business information” and “reveal pricing terms and other commercially sensitive information regarding non-parties to this action.” (Document No. 53, p. 3). Corporate Defendants note that the “Stipulated Protective Order” “protects, among other things, the ‘private information of an . . . entity’” and they contend that they “have, and will continue to, make a good faith effort to resolve the dispute pursuant to section 10 of the Stipulated

Protective Order.” (Document No. 53, pp. 3-4). In reply, Plaintiff argues that the “First Amendment governs the issue presented here,” and that “only a compelling governmental interest in secrecy can justify sealing a complaint, and even then the sealing must be narrowly tailored to serve that interest.” (Document No. 55, pp. 1-2). Although Plaintiff cites to caselaw requiring parties to “consider less drastic alternatives to sealing,” Plaintiff opposes any redactions to the Amended Complaint. (Document No. 55, p. 20 (quoting Virginia Dep’t of State Police v. Washington Post, 386 F.3d 567, 576 (4th Cir. 2004)). As an initial matter, the undersigned is not persuaded that capable and experienced counsel on both sides, who are familiar with this Court’s expectations, adequately conferred with each other in a good faith attempt to resolve their disagreement over the extent of appropriate redaction of the Amended Complaint. See LCvR 7.1(b); see also (Document No. 25, pp. 8-10). It appears the parties should have been able to agree on some minimal redactions before the deadline for filing the Amended Complaint, and to thereby completely avoid motions practice on this issue. After considering the parties’ briefs and cited legal authority, the Amended Complaint, and

the record, the undersigned will allow the unredacted version of the Amended Complaint (Document No. 40) to remain sealed and will direct Plaintiff to file a publicly-available redacted version of the Amended Complaint.

Free access — add to your briefcase to read the full text and ask questions with AI

FS Medical Supplies, LLC v. TannerGAP, Inc., (W.D.N.C. 2022).

FS Medical Supplies, LLC v. TannerGAP, Inc. (FS Medical Supplies, LLC v. TannerGAP, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Media General Operations, Inc. v. Buchanan
417 F.3d 424 (Fourth Circuit, 2005)